SCHEMBL15948708

SCHEMBL15948708

CC(=O)N1CC2CCN(C)C2C1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 3/20 0.47
CHRNA3 P32297 3/20 0.47
CHRNA4 P43681 3/20 0.47
CHRNB4 P30926 2/20 0.47
KMT5A Q9NQR1 1/20 0.42
CHRNB3 Q05901 1/20 0.39
CHRNA6 Q15825 1/20 0.39
L3MBTL3 Q96JM7 1/20 0.39
CYP1A2 P05177 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
CHRNA7 P36544 1/20 0.36
CHRM2 P08172 3/20 0.34
MEN1 O00255 1/20 0.34
CYP2D6 P10635 1/20 0.34
KMT2A Q03164 1/20 0.34
CHRM1 P11229 1/20 0.34
EPHX2 P34913 3/20 0.34
HRH3 Q9Y5N1 3/20 0.34
JAK1 P23458 1/20 0.33
JAK3 P52333 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9790975 0.85 KMT5A (0.42) CHRNB2CHRNA3CHRNA4CHRNB4KMT5A
SCHEMBL12505797 0.83 KMT5A (0.41) CHRNB2CHRNA3CHRNA4CHRNB4KMT5A
SCHEMBL13906189 0.81 KMT5A (0.36) KMT5AL3MBTL3HRH3
SCHEMBL18017249 0.81 CHRNB2 (0.47) CHRNB2CHRNA3CHRNA4CHRNB4CHRNB3
SCHEMBL18909241 0.80 CHRNB2 (0.51) CHRNB2CHRNA3CHRNA4CHRNB4KMT5A
SCHEMBL9345094 0.80 CHRNB2 (0.51) CHRNB2CHRNA3CHRNA4CHRNB4KMT5A
SCHEMBL14836434 0.78 CHRNB2 (0.44) CHRNB2CHRNA3CHRNA4CHRNB4CHRNB3
SCHEMBL9343895 0.78 GAA (0.45) TDP1CHRM1JAK1
SCHEMBL20744455 0.77 L3MBTL3 (0.46) KMT5AL3MBTL3CHRM2MEN1CYP2D6
SCHEMBL34473242 0.77 CHRNB2 (0.43) CHRNB2CHRNA3CHRNA4CHRNB4CHRNB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9181277-B2 Aminoquinazoline derivatives and their salts and methods of use SUNSHINE LAKE PHARMA CO., LTD. (CN) 2015-11-10 US disclosed
US-20140228361-A1 AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE SUNSHINE LAKE PHARMA CO., LTD. (CN) 2014-08-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140228361-A1 AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE ABL1, PRKDC, JAK2 CHRNB2 4023/4885CHRNA3 4057/4885CHRNA4 4598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.